Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4-9 positive lymph nodes

Breast

Volumn 22, Issue 5, 2013, Pages 682-690

  Saghatchian, M ^a,b   Mook, S ^b   Pruneri, G ^c   Viale, G ^c   Glas, A M ^d   Guerin, S ^a   Cardoso, F ^e   Piccart, M ^f   Tursz, T ^a   Delaloge, S ^a   van't Veer, L ^b,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY OF MILAN   (Italy)

^d Champalimaud Cancer Center ^*

^e Champalimaud Cancer Center   (Portugal)

^f JULES BORDET INSTITUTE   (Belgium)

Author keywords

4 9 Positive nodes; Breast; Cancer; Genomic; High risk; Prognostic

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DISTANT METASTASIS FREE SURVIVAL; DNA MICROARRAY; ESTROGEN RECEPTOR POSITIVE PROGESTERONE RECEPTOR NEGATIVE EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; FEMALE; FROZEN SECTION; GENE; GENE SIGNATURE; GENOMICS; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATIENT SELECTION; PRIMARY TUMOR; PRIORITY JOURNAL; RISK FACTOR;

4-9 POSITIVE NODES; BREAST; CANCER; GENOMIC; HIGH RISK; PROGNOSTIC;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; RNA, MESSENGER; SURVIVAL RATE;

EID: 84884127326     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.12.002     Document Type: Article

References (19)

1. Singletary S.E., Allred C., Ashley P., Bassett L.W., Berry D., Bland K.I., et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003, 83:803-819.
2. Veronesi U., Zurrida S., Viale G., Galimberti V., Arnone P., Nolè F. Rethinking TNM: a breast cancer classification to guide to treatment and facilitate research. Breast J 2009, 15:291-295.
3. Galea M.H., Blamey R.W., Elston C.E., Ellis I.O. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219.
4. Oakman C., Santarpia L., Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 2010, 7:725-732.
5. Colozza M., de Azambuja E., Cardoso F., Bernard C., Piccart M.J. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist 2006, 11:111-125.
6. Piccart M.J., Sotiriou C., Cardoso F. New data on chemotherapy in the adjuvant setting. Breast 2003, 12:373-378.
7. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
8. Cardoso F., Van't Veer L., Rutgers E., Loi S., Mook S., Piccart-Gebhart M.J. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008, 26:729-735.
9. Mook S., Van't Veer L.J., Rutgers E.J., Piccart-Gebhart M.J., Cardoso F. Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics 2007, 4:147-155.
10. Nieto Y., Shpall E.J. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?. Curr Opin Oncol 2009, 21:150-157.
11. Blamey R.W., Hornmark-Stenstam B., Ball G., Blichert-Toft M., Cataliotti L., Fourquet A., et al. ONCOP. Eur J Cancer 2010, 46:56-71.
12. Crabb S.J., Bajdik C.D., Leung S., Speers C.H., Kennecke H., Huntsman D.G., et al. Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Res 2008, 10:R6.
13. Acharya C.R., Hsu D.S., Anders C.K., Anguiano A., Salter K.H., Walters K.S., et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 2008, 299:1574-1587.
14. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144.
15. Moebus V., Jackisch C., Lueck H.J., du Bois A., Thomssen C., Kurbacher C., et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010, 28:2874-2880.
16. Boccardo F., Amadori D., Guglielmini P., Sismondi P., Farris A., Agostara B., et al. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. Oncology 2010, 78:274-281.
17. Straver M.E., Glas A.M., Hannemann J., Wesseling J., van de Vijver M.J., Rutgers E.J., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010, 119:551-558.
18. Knauer M., Mook S., Rutgers E.J., Bender R.A., Hauptmann M., van de Vijver M.J., et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010, 120:655-661.
19. Albain K.S., Barlow W.E., Shak S., Hortobagyi G.N., Livingston R.B., Yeh I.T., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11:55-65.